Clinical Trials Logo

Influenza clinical trials

View clinical trials related to Influenza.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT04912180 Terminated - Influenza Clinical Trials

Apple Respiratory Study

ARS
Start date: April 6, 2021
Phase:
Study type: Observational

The Apple Respiratory Study, a collaboration between researchers at Apple Inc. (the "Study Sponsor" or "Sponsor") and the Seattle Flu Study team at the University of Washington (UW) (the "UW Study Team"), is a prospective, longitudinal cohort, low risk Study to collect certain data from Apple Watch and iPhone to determine whether such data can detect physiologic and non-physiologic changes in individuals associated with respiratory illnesses due to influenza, SARS-CoV-2 and other respiratory pathogens (the "Study").

NCT ID: NCT04664075 Terminated - Covid19 Clinical Trials

Predicting Severity and Disease Progression in Influenza-like Illness (Including COVID-19)

PREDICT-ILI
Start date: January 25, 2021
Phase:
Study type: Observational

Respiratory infections such as colds, flu and pneumonia affect millions of people around the world every year. Most cases are mild, but some people become very unwell. Influenza ('flu') is one of the most common causes of lung infection. Seasonal flu affects between 10% and 46% of the population each year and causes around 12 deaths in every 100,000 people infected. In addition, both influenza and coronaviruses have caused pandemics in recent years, leading to severe disease in many people. Although flu vaccines are available, these need to change every year to overcome rapid changes in the virus and are not completely protective. This study aims to find and develop predictive tests to better understand how and when flu-like illness progresses to more severe disease. This may help to decide which people need to be admitted to hospital, and how their treatment needs to be increased or decreased during infection. The aim is to recruit 100 patients admitted to hospital due to a respiratory infection. It is voluntary to take part and participants can choose to withdraw at any time. The study will involve some blood and nose samples. This will be done on Day 0, Day 2 and Discharge from hospital, and an out-patient follow-up visit on Day 28. The data will be used to develop novel diagnostic tools to assist in rational treatment decisions that will benefit both individual patients and resource allocation. It will also establish research preparedness for upcoming pandemics.

NCT ID: NCT04377165 Terminated - Influenza Clinical Trials

Innovative Tool to Limit Spread of COVID 19 in Residential Aged Care Facilities

Start date: May 6, 2020
Phase: N/A
Study type: Interventional

This project is a randomised trial in order to determine if "gamification" can result in behaviour change for healthcare workers in the residential aged care setting. The app is for Age Care and care workers at the front line who are working to protect those most vulnerable to COVID-19. There are 2 groups in this trial on group will receive current and accurate information from an app. The other group will receives the app with the addition of a gamification competent, this will include rewarding experiences for staff doing safety behaviours and wellbeing behaviours. The purpose of the gamification is to create a calming and reassuring experience that injects positivity and joy where possible during this stressful time.

NCT ID: NCT04141917 Terminated - Influenza Clinical Trials

Test-and-treat for Influenza in Homeless Shelters

Start date: November 15, 2019
Phase: Phase 4
Study type: Interventional

This study is a stepped-wedge cluster-randomized trial of on-site rapid testing and treatment for influenza in homeless shelters within the Seattle area to determine whether this strategy reduced the incidence of influenza in the shelter environment.

NCT ID: NCT03880474 Terminated - Influenza Clinical Trials

Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults

Start date: March 18, 2019
Phase: Phase 2
Study type: Interventional

A Phase 2b Study to Determine the Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults aged 18 years and over. To assess the effect of MVA-NP+M1 on the reduction of laboratory confirmed influenza when given as an adjunct to licensed quadrivalent influenza vaccine (QIV) in adults

NCT ID: NCT03686514 Terminated - Influenza Clinical Trials

The Impact of Imprinting and Repeated Influenza Vaccination on Adaptive Immunity, Transcriptomics, and Metabolomics

FLU2
Start date: October 22, 2018
Phase: Phase 4
Study type: Interventional

The goal of this study is to understand the impact on the human immune system's response to the four strain flu vaccine in individuals who have "imprinted" on specific influenza strains. It will also consider the effects of repeated prior annual influenza vaccination on the immune system.

NCT ID: NCT03300362 Terminated - Influenza Clinical Trials

Improved Novel VaccIne CombinaTion InflUenza Study

INVICTUS
Start date: October 13, 2017
Phase: Phase 2
Study type: Interventional

A Phase IIb randomised, participant-blinded, placebo-controlled, multi-centre phase IIb efficacy study in 2030 volunteers aged 65 and over. The study will assess the safety and efficacy of the co-administration of a viral vectored vaccine, MVA- NP+M1, and the annual recommended licensed inactivated influenza vaccine (IIV). Within the main cohort 100 participants will be recruited to an immunology sub-cohort.

NCT ID: NCT03023709 Terminated - Influenza Clinical Trials

Tissue-specific Responses to Influenza Immunization and Their Relation to Blood Biomarkers (SLVP032)

Start date: September 2015
Phase: Phase 4
Study type: Interventional

The investigators collected blood and lymphoid tissues routinely discarded during surgery from adults after a routine seasonal influenza vaccination to determine how immune memory develops at the actual site of infection, and how immunization may alter this process.

NCT ID: NCT03020472 Terminated - Influenza Clinical Trials

Kinetics of B-Cell Responses to Live, Attenuated Influenza Vaccine (LAIV) in Young Children Two Years of Age

SLVP016
Start date: November 2008
Phase: Phase 4
Study type: Interventional

This pilot study will investigate B-cell responses following vaccination with live, attenuated influenza vaccine (LAIV) in healthy children 2 years of age from blood samples taken at designated time points before and after vaccination.

NCT ID: NCT02883426 Terminated - Influenza Clinical Trials

Evaluating the Safety and Immunogenicity of a Live Attenuated Virus Vaccine to Prevent Influenza H3N2v Disease

Start date: September 2016
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety and immunogenicity of the H3N2v MN 2010/AA ca live attenuated influenza vaccine (H3N2v LAIV) in healthy children and adults, 6 to 26 years old.